clinical trial · NCT06194318
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
Clover Biopharmaceuticals AUS Pty·phase1·completed·n = 160
Respiratory Syncytial Virus VaccinationCandidate vaccine, SCB-1019placebocandidate vaccine, SCB-1019TAREXVY
brief summary
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
started
Dec 13, 2023
primary completion
Feb 26, 2025
completion
May 7, 2025
last updated
Jun 6, 2025
detailed description
A Phase 1, placebo-controlled, randomized, observer-blind, First-in-human Study to describe the Safety, reactogenicity and immunogenicity of a bivalent recombinant RSV vaccines (SCB-1019 and SCB-1019T) in healthy adults
official title
Phase 1, Placebo-controlled, Randomized, Observer-blind, First-in-human Study of Bivalent RSV Prefusion F Protein Vaccines (SCB-1019/SCB-1019T) in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol